Common and Specific Information From Neuroimaging and Smartphone

NCT05482906 · tracked via the Priya Life Science France tracker

Sponsor

Nantes University Hospital

Phase

Observational

Started

2023-04-03

Last updated

2026-03-13

Condition(s) studied

Multiple Sclerosis

Investigational drug(s) / intervention(s)

eGait

eGait: IMU sensor (as part of eGait device) worn at the hip during T25FW

Study summary

Gait alteration is frequent in MS and limitation in walking ability is a major concern in MS patients. Umanit and LMJL (Nantes university) has developed a device call egait to assess walking ability in individuals (eg MS patients).

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria : * Diagnosis of MS based on McDonald criteria (including Relapsing-remitting and progressive MS) * Over 18 years old /age greater than 18 years * Patients followed at Nantes university hospital or Rennes university hospital * Last known EDSS before inclusion ranging from 0 to 6 inclusive/EDSS of 0 to 6 inclusive, prior inclusion * No relapse within 3 months * With a Medullar MRI planed as part as usual care * MRI scan can be performed within a maximum of 4 months after or before the walking test. * Affiliated person or beneficiary of a social security scheme Exclusion Criteria : * Bilateral aid needed to walk * Women who are pregnant * Patient having expressed their opposition * Patient under guardianship or security measure

Primary outcome measure(s)

Clustering analyze based on IGP — At the inclusion
IGP consists of a curve, based on quaternion and representing the rotation recorded by the IMU during an average gait cycle (0-1).
Clustering analyze based on EDSS score — At the inclusion
EDSS is an ordinal scale measuring disability and ranging from 0 (normal examination) to 10 (death due to MS) in a 0,5-point increments from score 1.
Clustering analyze based on MRI lesion load — At the inclusion
MRI characteristics are spinal and extraspinal lesion volumes.

Trial sites (1)

Facility	City	Region	Status
Nantes University Hospital	Nantes	Loire-Atlantique	Recruiting

More Nantes University Hospital trials in France

Pilot Study on the Adaptation and Tolerance of Essilor® Myopia-control Spectacle Lenses Recruiting

Characterization and Support for Neurodevelopmental Disorders Associated With Congenital Heart Defects Recruiting

French Clinical Datbase of Melanoma Patients (RIC-Mel) Recruiting

Research Project on the Risk of Discomfort, Pain, Alteration of Skin Condition in Bedpan Use by Patients and Caregivers Recruiting

Optimization of Skin Preparation to Reduce Cutibacterium Acnes Colonization in Superficial and Deep Samples During Prosthetic Shoulder Surgery in Male Patients Recruiting

Other trials for the same condition

3D OPTIMIZED WMN MPRAGE Increased Detection of Focal Spinal Cord Lesion in Multiple Sclerosis (WHINUME) Recruiting

Grey Matter Damage at the Earliest Phase of Multiple Sclerosis : a Longitudinal 7T MRI Study Active, not recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) Active, not recruiting

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis Active, not recruiting

Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05482906 on ClinicalTrials.gov ↗ ← All trials in France